Adverse events reported in the package insert for olanzapine include dry mouth, dizziness, sedation, insomnia, orthostatic hypotension, akathisia, and weight gain. Olanzapine is reported to cause extra pyramidal symptoms, tardive dyskinesia and neuroleptic malignant syndrome, although at a much reduced rate when compared to the classical anti-psychotics.
Recently the FDA required the manufacturers of all atypical antipsychotic to include a warning about the risk of hyperglycemia and diabetes with atypical antipsychotic. Additionally there are some case reports of olanzapine-induced diabetic ketoacidosis. There is data showing that olanzapine can decrease insulin sensitivity. In addition, increased triglyceride levels may also be an issue with olanzapine. Impaired glucose metabolism, high triglycerides, and obesity have been shown to be constituents of the metabolic syndrome and may increase the risk of cardiovascular disease. The data suggests that olanzapine may be more likely to cause adverse metabolic effects than some of the other atypical antipsychotic.
![]() | |
![]() | |
![]() | ![]() |
Powered By widgetmate.com | Sponsored By Apply for Credit Cards |
February 2006 September 2006 November 2006 December 2006 January 2007 February 2007 March 2007 April 2007 May 2007 June 2007 November 2007